Free Shipping for orders over $49 within the U.S.

Lifeflower® Breviscapine (Erigeron Breviscapus Extract)

Lifeflower® supports brain & cerebrovascular health.

LifeFlower® Breviscapine (Erigeron Breviscapus extract) is a patented and branded ingredient that contains at least 90% of scutellarin as the primary bioactive compound. It is extracted from Erigeron Breviscapus, a medicinal plant that has been used for over 500 years. LifeFlower® Breviscapine is GRAS self-affirmed to be used as an ingredient in food, beverage and dietary supplement. The recommended dosage is 200mg per person per day as dietary supplement, 84mg per person per serving in food and beverage.

Product Details

BRE-002 Lifeflower® Breviscapine (Erigeron Breviscapus Extract)(Scutellarin ≥98%, HPLC) 

BRE-003 Lifeflower® Breviscapine (Erigeron Breviscapus Extract)(Scutellarin ≥90%, HPLC)

Molecular Formula: C12H18O12

Molecular Weight: 462.36

CAS#: 116122-36-2

Chemical Nature: Dietary Ingredient

Common Name: Erigeron Breviscapus Extract, Scutellarin, Breviscapinum

Quality Control Seed-to-Sale Traceability

  • GAP Cultivation
  • cGMP Manufacturing
  • GSP Logistic & Warehousing
  • Independent Verify Quality
  • FDA Compliance

Scientific Evidence

Please click here to read more at farlong.us

Additional studies of breviscapine or scutellarin are documented on the PubMed.gov website, NCBI (US National Library of Medicine National Institute of Health). Search using key words: Breviscapine, Scutellarin, Erigeron Breviscapus

Applications

  • Baked Food
  • Sports Drink
  • Smoothie
  • Yoghurt
  • Dietary Supplement

Estimated Daily Intake

200mg/day as Supplement

84mg/day as Food & Beverage Ingredient

Appearance & Taste

  • Light Yellow Fine Powder
  • Neutral Taste

Self-Affirmed GRAS | cGMP | Vertical Integration

Following Test Report Available Upon Request

Jing Ma  2017a.  A Single Dose Toxicity Study of Breviscapine for Injection in Sprague Dawley Rats via Intravenous Injection.  Study No. 1610AD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  May 23, 2018, pp. 64. 

Jing Ma  2017b.  The toxicity test data and literature for rats with repeated administration.  The toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period.  Study No. 1016RD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 4. 

Jing Ma  2017c.  The toxicity test data and literature for Beagle dogs with repeated administration.  The toxicity test on Beagle dogs receiving 4-week repeated intravenous injection with breviscapine injection in the 4-week recovery period.  Study No. 1016RD2.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 3. 

Jing Ma  2017d.  Test data and literature for anaphylactic (systemic) special safety.  Active systemic anaphylaxis test for guinea pigs with the administration of breviscapine injection.  Study No. 1610HY2.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 4, 2018, summary of test results, pp. 3. 

Jing Ma  2017e.  Test data and literature for the special safety of hemolysis.  Hemolysis test for the breviscapine injection.  Study No. 1610HL1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  May 14, 2018, summary of test results, pp. 2. 

Jing Ma  2017f.  The toxicity test data and literature for rats with repeated administration.  The toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapineinjection in 4-week recovery period with micronucleus test.  Study No. 1016RD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 4. 

Jing Ma  2017g.  Test data and literature of genetic toxicity.  Bacterial reverse mutation test for the breviscapine injection.  Study No. 1610AM1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  April 19, 2018, summary of test results, pp. 2. 

Jing Ma  2017h.  Genetic toxicity test data and literature.  The micronucleus test on SD rats receiving intravenous injection with breviscapine injection.  The accompanied toxicity test on SD rats receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period.  Study No. 1610RD1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 28, 2018, summary of test results, pp. 2. 

Jing Ma  2017i.  Test data and literature of genetic toxicity.  The chromosome aberration test on Chinese hamster lung fibroblast cell line for the breviscapine injection.  Study No. 1016CA1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  April 9, 2018, summary of test results, pp. 3. 

Jing Ma  2017j.  Test data and literature for genetic toxicity.  The comet assay on SD rats receiving the intravenous injection with breviscapine injection.  Study No. 1610CO1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  July 6, 2018, summary of test results, pp. 3. 

Jing Ma  2017k.  Test data and literature for reproductive toxicity.  The toxicity test of reproduction and early embryonic development for SD rats receiving the intravenous injection with breviscapine injection.  Study No. 1610RA1.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  March 14, 2018, summary of test results, pp. 3. 

Jing Ma  2017l.  Test data and literature for special safety of local irritation.  The irritation test on administration sites of Beagle dogs receiving intravenous injection with breviscapine injection.  The accompanied toxicity test on Beagle dogs receiving 4-week repeated intravenous injection with breviscapine injection in 4-week recovery period.  Study No. 1016RD2.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  March 14, 2018, summary of test results, pp. 2. 

Jing Ma  2017m.  Test data and literature for anaphylactic (systemic) special safety.  The passive cutaneous anaphylaxis test for rats receiving the breviscapine injection.  Study No. 1016HY4.  Conducted at Shanghai InnoStar Bio-Tech Co., LTD. (InnoStar).  National Shanghai Center for New Drug Safety Evaluation and Research (NCDSER).  199 Guoshoujing Road, Pilot Free Trade Zone, Shanghai, Peoples Republic of China.  June 4, 2018, summary of test results, pp. 3. 

Order Now

To order our raw materials, call us at 1-888-327-5664, e-mail us at social@farlong.com or fill out the form below.